Promises and Limitations of Neural Stem Cell Therapies for Progressive Multiple Sclerosis.
neural stem cells
neuroinflammation
progressive multiple sclerosis
regenerative medicine
regenerative neuroimmunology
stem cell therapies
Journal
Trends in molecular medicine
ISSN: 1471-499X
Titre abrégé: Trends Mol Med
Pays: England
ID NLM: 100966035
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
14
02
2020
revised:
08
04
2020
accepted:
26
04
2020
pubmed:
26
5
2020
medline:
9
7
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Multiple disease-modifying medications with regulatory approval to treat multiple sclerosis (MS) are unable to prevent inflammatory tissue damage in the central nervous system (CNS), and none directly promote repair. Thus, there is an unmet clinical need for therapies that can arrest and reverse the persistent accumulation of disabilities associated with progressive forms of MS (P-MS). Preclinical research has revealed an unexpected ability of neural stem cell (NSC) therapies to provide neurotrophic support and inhibit detrimental host immune responses in vivo following transplantation into the chronically inflamed CNS. We discuss NSC transplantation as a promising therapy for P-MS, elaborate on the necessities of clinical trial validation and formalized usage guidelines, and caution about unscrupulous 'clinics' marketing unproven therapies to patients.
Identifiants
pubmed: 32448751
pii: S1471-4914(20)30123-4
doi: 10.1016/j.molmed.2020.04.005
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
898-912Informations de copyright
Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.